News Articles and Montana BioScience Alliance Newsletters

MONTANA BIOSCIENCE ENTERPRISES IN THE NEWS

At first glance, a room in the basement of McGill Hall on the University of Montana campus appears like a private gym with treadmills, dumbbells and exercise bikes.  It seems like a good place for a workout. But the space is actually a research laboratory for students and faculty in UM’s School of Integrative Physiology and Athletic Training within the College of Health. 

University of Montana
|
March 20, 2024

Doug Brinkerhoff intends to use computer deep learning to improve predictions of sea level rise from melting ice sheets. Beverly Piggott will study how brain cells regulate their own acidity during development.

A team of scientists from Montana State University recently published unique research examining how individual cells respond to viral infection. The work used state-of-the-art technology to culture cells and track infection in real time; it is the first known project to use microfluidic technology to culture, infect and track infection on a single-cell level. 

A Montana State University researcher was recently awarded a $2.76 million, five-year grant from the National Institutes of Health to help find pre-symptom evidence of the onset of osteoarthritis, a disease that affects one in seven Americans. 

Wintermute Biomedical has successfully raised USD 1.3 million from investors to propel its groundbreaking Shingles treatment, Solexan™, into a Phase Ib clinical trial. The primary focus of this randomized double-blind placebo-controlled trial is to assess the safety, tolerability, and proof-of-concept efficacy of Solexan™ in reducing shingles-related pain and expediting lesion healing.

ARTICLES OF INTEREST

When her husband was undergoing cancer treatment, Cindy Perez of Southwest Ranches, Fla., learned about a new blood test that could help find early cancers. The 50-year-old said she felt fine, but her husband urged her to take the test anyway.

National Institutes of Health
|
March 26, 2024

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.

BIO.News
|
January 30, 2024

As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.

NIH National Institute on Aging
|
January 18, 2024

Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR

National Institutes of Health SEED
|
January 18, 2024

Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.

NEWSLETTER

Newsletter
|
August 26, 2024

View the September 2024 Newsletter now!

Newsletter
|
July 25, 2024

View the Summer 2024 Newsletter now!